JUAN MARÍA
BLANCO MADRIGAL
Sociedad Española de Reumatología
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Sociedad Española de Reumatología (5)
2024
-
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
Seminars in Arthritis and Rheumatism, Vol. 64
-
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199
2022
-
Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry (Rheumatology and Therapy, (2022), 9, 4, (1031-1047), 10.1007/s40744-022-00446-9)
Rheumatology and Therapy
-
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Rheumatology and Therapy, Vol. 9, Núm. 4, pp. 1031-1047
2021
-
Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
Scientific Reports, Vol. 11, Núm. 1